Dengue virus, a life-debilitating, potentially deadly mosquito-borne virus that infects 400 million people, hospitalizes 1.5 million and kills 100,000+ annually.
Ennaid Therapeutics is using its unique platform technology of flavivirus fusion inhibitors to develop cures for all four strains of Dengue virus.
We welcome strategic partnerships, as partnerships accelerate the development of our cures from the lab to the people who need them.
“At Ennaid Therapeutics, we recognize the vast amount of good science sitting on research shelves waiting to be positively exploited for use in humans and animals. Therefore, we are committed to translating complex science into today’s cures to help patients live healthier, more abundant lives. We have made great strides as a company and have a promising technology, an accelerated plan and an expert team to develop and commercialize cures for Dengue virus and West Nile virus.”
“We have the technology, the plan and the team to develop & commercialize cures for Dengue & West Nile Virus.”